Atlas Trials

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Clinical trial NCT05305924 · RECRUITING

Trial details

NCT number
NCT05305924
Sponsor
The Methodist Hospital Research Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
ER-Positive Breast CancerHER2-negative Breast Cancer
Start date
2021-02-25
Primary completion
2026-12-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.